IgA肾病临床实践模式:全球问卷调查研究
该全球问卷调查研究纳入422名肾脏科医生,旨在了解IgA肾病的诊疗策略。结果显示,97.2%的医生使用RAAS阻断剂作为初始治疗,但其他支持治疗和免疫抑制启动时机存在异质性;仅30.4%的医生将持续性蛋白尿>1 g/d的患者纳入临床试验,低收入和中等收入国家(LMICs)仅8.1%。
要点
- 97.2%肾脏科医生使用RAAS阻断剂作为IgA肾病初始治疗。
- 92.4%医生在蛋白尿>1 g/d持续≥3个月时启动免疫抑制。
- 仅30.4%医生将蛋白尿>1 g/d患者纳入临床试验,LMICs仅8.1%。
核心结论
- 大多数肾脏科医生在IgA肾病临床严重度评估参数、RAAS阻断剂使用和血压控制上达成共识,但其他支持治疗和免疫抑制启动存在异质性。
- 医生对将患者纳入新疗法临床试验持 reluctance,尤其在LMICs。
研究设计与样本
- 全球在线两步问卷调查,纳入422名肾脏科医生完成初始调查,339名完成随访调查。
- 调查聚焦IgA肾病各种管理策略。
主要发现
- 13.7%的医生未在活检报告中获取MEST-C评分。
- 97.2%的医生使用ACEi/ARB进行RAAS阻断作为初始治疗。
- 其他支持治疗包括鱼油(43.6%)和SGLT2抑制剂(48.6%),存在地区差异。
- 92.4%的医生在蛋白尿>1 g/d持续≥3个月时启动免疫抑制。
- 启动免疫抑制的主要考虑因素:蛋白尿水平(87.9%)、eGFR下降(78.7%)、对RAAS阻断无反应(57.6%)、MEST-C评分(64.9%)。
临床怎么用
- 多数医生采用RAAS阻断和血压控制作为基础治疗,但其他支持治疗和免疫抑制启动需结合地区实践和患者因素个体化决策。
- 应关注临床试验参与的地域差异,尤其需促进LMICs患者入组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: IgA nephropathy (IgAN) displays ethnic differences in disease phenotype. We aimed to examine how this common disease is managed worldwide. METHODS: An online 2-step questionnaire-based survey was conducted among nephrologists globally focusing on various management strategies used in IgAN. RESULTS: A total of 422 nephrologists responded to the initial survey and 339 to the follow-up survey. Of the nephrologists, 13.7% do not get MEST-C scores in biopsy reports; 97.2% of nephrologists use renin-angiotensin-aldosterone system (RAAS) blockade with angiotensin-converting-enzyme inhibitors (ACEi) / angiotensin receptor blockers (ARB) as initial treatment. Other supportive treatments commonly employed are fish oil (43.6%) and sodium-glucose co-transporter-2 (SGLT2) inhibitors (48.6%) with regional differences. Immunosuppression is generally (92.4%) initiated when proteinuria >1 g/d persists for ≥3 months.Main considerations for initiating immunosuppression are level of proteinuria (87.9%), estimated glomerular filtration rate (eGFR) decline (78.7%), lack of response to RAAS blockade (57.6%) and MEST-C score (64.9%). Corticosteroids (89.1%) are universally used as first-line immunosuppression; mycophenolate mofetil is commonly used in resistant patients (49.3%). Only 30.4% nephrologist enroll patients with persistent proteinuria >1 g/d in clinical trials. Nephrologists in Europe (63.6%), North America (56.5%), and Australia (63.6%) are more likely to do so compared to South America (31.3%) and Asia (17.2%). Only 8.1% nephrologists in lower-middle income countries (LMICs) enroll patients in clinical trials, though 40% of them are aware of such trials in their nations. CONCLUSION: Although most nephrologists agree on common parameters to assess clinical severity of IgAN, use of RAAS blockade, and blood pressure control, there is heterogeneity in use of other supportive therapies and initiation of immunosuppression. There is reluctance to enroll patients in clinical trials with novel treatments, principally in LMICs.
引用
- Bansal B, Grewal A, Teo BW, et al. Clinical Practice Patterns in IgA Nephropathy: A Global Questionnaire-Based Survey. Kidney Int Rep. 2023. PMID: 38106584. doi:10.1016/j.ekir.2023.09.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。